Tomas Odergren

2.1k total citations
35 papers, 1.6k citations indexed

About

Tomas Odergren is a scholar working on Neurology, Epidemiology and Physiology. According to data from OpenAlex, Tomas Odergren has authored 35 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Neurology, 9 papers in Epidemiology and 7 papers in Physiology. Recurrent topics in Tomas Odergren's work include Neurological disorders and treatments (10 papers), Acute Ischemic Stroke Management (9 papers) and Botulinum Toxin and Related Neurological Disorders (8 papers). Tomas Odergren is often cited by papers focused on Neurological disorders and treatments (10 papers), Acute Ischemic Stroke Management (9 papers) and Botulinum Toxin and Related Neurological Disorders (8 papers). Tomas Odergren collaborates with scholars based in Sweden, United Kingdom and United States. Tomas Odergren's co-authors include Tim Ashwood, Kristian Borg, Bo‐Lennart Johansson, J. Wahren, E. Fernqvist‐Forbes, A. Richard Green, Jörgen Borg, Sharon Stone‐Elander, Martin Ingvar and A Kernell and has published in prestigious journals such as Brain, Neurology and Stroke.

In The Last Decade

Tomas Odergren

34 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tomas Odergren Sweden 18 644 372 320 302 266 35 1.6k
Catherine Marchand‐Leroux France 30 835 1.3× 525 1.4× 386 1.2× 297 1.0× 782 2.9× 56 2.5k
Isabel Saul United States 25 344 0.5× 389 1.0× 322 1.0× 283 0.9× 489 1.8× 43 1.6k
Revital Duvdevani Israel 18 556 0.9× 218 0.6× 263 0.8× 337 1.1× 485 1.8× 24 1.5k
Izumi Harukuni United States 15 254 0.4× 324 0.9× 185 0.6× 377 1.2× 440 1.7× 26 1.6k
Leontino Battistin Italy 23 492 0.8× 313 0.8× 301 0.9× 379 1.3× 399 1.5× 53 2.0k
Haiyan Zhou China 23 646 1.0× 213 0.6× 223 0.7× 362 1.2× 473 1.8× 104 1.6k
Hahn Young Kim South Korea 24 299 0.5× 620 1.7× 417 1.3× 203 0.7× 376 1.4× 76 1.8k
Yoshio Ikeda Japan 28 810 1.3× 428 1.2× 473 1.5× 493 1.6× 914 3.4× 136 2.8k
Patrick Gelé France 19 396 0.6× 375 1.0× 212 0.7× 265 0.9× 1.2k 4.5× 33 2.2k
I. Mhairi Macrae United Kingdom 25 346 0.5× 587 1.6× 415 1.3× 368 1.2× 402 1.5× 55 2.1k

Countries citing papers authored by Tomas Odergren

Since Specialization
Citations

This map shows the geographic impact of Tomas Odergren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomas Odergren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomas Odergren more than expected).

Fields of papers citing papers by Tomas Odergren

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomas Odergren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomas Odergren. The network helps show where Tomas Odergren may publish in the future.

Co-authorship network of co-authors of Tomas Odergren

This figure shows the co-authorship network connecting the top 25 collaborators of Tomas Odergren. A scholar is included among the top collaborators of Tomas Odergren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomas Odergren. Tomas Odergren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zachrisson, Olof, Malin Johannesson, Linda Söderberg, et al.. (2025). Exidavnemab binds to aggregated α-synuclein in human brains affected by α-synucleinopathies. Neurotherapeutics. 23(1). e00779–e00779.
2.
Xiong, Hao, Cindy Zadikoff, Qingbo Li, et al.. (2024). Safety, Tolerability, and Pharmacokinetics of Single Doses of Exidavnemab (BAN0805), an Anti‐α‐Synuclein Antibody, in Healthy Western, Caucasian, Japanese, and Han Chinese Adults. The Journal of Clinical Pharmacology. 64(11). 1432–1442. 2 indexed citations
3.
Gkanatsiou, Eleni, Charlotte Sahlin, Erik Portelius, et al.. (2021). Characterization of monomeric and soluble aggregated Aβ in Down’s syndrome and Alzheimer’s disease brains. Neuroscience Letters. 754. 135894–135894. 13 indexed citations
4.
Johannesson, Malin, Charlotte Sahlin, Linda Söderberg, et al.. (2021). Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease. Molecular and Cellular Neuroscience. 114. 103641–103641. 20 indexed citations
5.
Cucchiara, Brett, Scott E. Kasner, David A. Wolk, et al.. (2004). Early impairment in consciousness predicts mortality after hemispheric ischemic stroke. Critical Care Medicine. 32(1). 241–245. 49 indexed citations
6.
Green, A. Richard, Tomas Odergren, & Tim Ashwood. (2003). Animal models of stroke: do they have value for discovering neuroprotective agents?. Trends in Pharmacological Sciences. 24(8). 402–408. 131 indexed citations
7.
Ashwood, Tim, et al.. (2003). Nitrones as neuroprotective agents in cerebral ischemia, with particular reference to NXY-059. Pharmacology & Therapeutics. 100(3). 195–214. 78 indexed citations
8.
Ekblom, Marianne, Tomas Odergren, Tim Ashwood, et al.. (2003). Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients. British Journal of Clinical Pharmacology. 56(2). 173–183. 29 indexed citations
9.
Ekblom, Marianne, et al.. (2003). Pharmacokinetics and sedative effects in healthy subjects and subjects with impaired liver function after continuous infusion of clomethiazole. European Journal of Clinical Pharmacology. 59(2). 117–122. 7 indexed citations
10.
Barer, D H, et al.. (2002). Safety and tolerability of NXY-059 at higher target concentrations in acute stroke patients. Stroke. 1 indexed citations
11.
Borga, Magnus, et al.. (2002). Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke. European Journal of Clinical Pharmacology. 58(6). 409–415. 23 indexed citations
12.
Odergren, Tomas, Haukur Hjaltason, Seppo Kaakkola, et al.. (1998). A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport  and Botox  in the treatment of cervical dystonia. Journal of Neurology Neurosurgery & Psychiatry. 64(1). 6–12. 228 indexed citations
13.
Lyden, Patrick D., T. Ashwood, L. Claesson, et al.. (1998). The clomethiazole acute stroke study in ischemic, hemorrhagic, and t-PA treated stroke: Design of a phase III trial in the united states and canada. Journal of Stroke and Cerebrovascular Diseases. 7(6). 435–441. 22 indexed citations
14.
Odergren, Tomas, Sharon Stone‐Elander, & Martin Ingvar. (1998). Cerebral and cerebellar activation in correlation to the action‐induced dystonia in Writer's cramp. Movement Disorders. 13(3). 497–508. 118 indexed citations
15.
Johansson, Bo‐Lennart, Kristian Borg, E. Fernqvist‐Forbes, et al.. (1996). C-peptide improves autonomic nerve function in IDDM patients. Diabetologia. 39(6). 687–695. 111 indexed citations
16.
Odergren, Tomas, Naoya Iwasaki, Jörgen Borg, & Hans Forssberg. (1996). Impaired sensory–motor integration during grasping in writer’s cramp. Brain. 119(2). 569–583. 87 indexed citations
17.
Odergren, Tomas, et al.. (1996). Activation and suppression of the sternocleidomastoid muscle induced by transcranial magnetic stimulation. Electroencephalography and Clinical Neurophysiology/Electromyography and Motor Control. 101(2). 175–180. 14 indexed citations
18.
Odergren, Tomas, A Tollbäck, & Jörgen Borg. (1994). Efficacy of botulinum toxin for cervical dystonia. A comparison of methods for evaluation. Journal of Rehabilitation Medicine. 26(4). 191–195. 1 indexed citations
19.
Odergren, Tomas, A Tollbäck, & Jörgen Borg. (1994). Efficacy of botulinum toxin for cervical dystonia. A comparison of methods for evaluation. Journal of Rehabilitation Medicine. 26(4). 191–195. 17 indexed citations
20.
Odergren, Tomas, A Tollbäck, & Jörgen Borg. (1994). Electromyographic single motor unit potentials after repeated botulinum toxin treatments in cervical dystonia. Electroencephalography and Clinical Neurophysiology/Evoked Potentials Section. 93(5). 325–329. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Catherine Marchand‐Leroux Breakdown of academic impact, for papers by Isabel Saul Breakdown of academic impact, for papers by Revital Duvdevani Breakdown of academic impact, for papers by Izumi Harukuni Breakdown of academic impact, for papers by Leontino Battistin Breakdown of academic impact, for papers by Haiyan Zhou Breakdown of academic impact, for papers by Hahn Young Kim Breakdown of academic impact, for papers by Yoshio Ikeda Breakdown of academic impact, for papers by Patrick Gelé Breakdown of academic impact, for papers by I. Mhairi Macrae
Rankless by CCL
2026